<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294433</url>
  </required_header>
  <id_info>
    <org_study_id>Study 11022017</org_study_id>
    <nct_id>NCT04294433</nct_id>
  </id_info>
  <brief_title>Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children</brief_title>
  <official_title>Clinical Trial to Assess Immunogenicity of 2 Versus 3 Doses of Hepatitis B Vaccines When Administered to Children Aged 2 to 18 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare the immunogenicity of the hepatitis B
      component in children vaccinated with (I) two doses of Infanrix-hexa administered at 2 and 12
      months of age versus (II) one dose of Infanrix-hexa and one dose of Twinrix administered
      respectively at 2 and 12 months of age versus (III) three doses of Infanrix-hexa administered
      at 2, 4 and 18 months of age (comparator).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the province of Quebec, Canada, hepatitis B vaccination of infants involves three doses of
      vaccine, 2, 4 and 18 months of age. However, in the current epidemiological context (virtual
      absence of new cases in young Quebecers) and taking into account scientific data which
      consistently show a high immunogenicity and efficacy of two doses of hepatitis B vaccine, the
      relevance of the second dose given at the age of 4 months is questionable.

      this study is designed to compare the immunogenicity of the hepatitis B component in children
      vaccinated with (I) two doses of Infanrix-hexa administered at 2 and 12 months of age versus
      (II) one dose of Infanrix-hexa and one dose of Twinrix administered respectively at 2 and 12
      months of age versus (III) three doses of Infanrix-hexa administered at 2, 4 and 18 months of
      age (comparator).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised 1:1 for 2 study groups. Non-randomised for comparator group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>1 month post last dose of vaccine</time_frame>
    <description>The proportion of children with an anti-HBs titer ≥10mIU/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune memory</measure>
    <time_frame>36 months post last primary vaccine dose</time_frame>
    <description>Immune response to a booster dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Infanrix-hexa+Infanrix-hexa+Infanrix-hexa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children vaccinated at the age of 2, 4 and 18 months with a standard dose of Infanrix-hexa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infanrix-hexa+Infanrix-hexa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infanrix-hexa+Twinrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children vaccinated at the age of 2 and 18 months with a standard dose of Infanrix-hexa and a standard dose of Infanrix-Junior, respectively</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix-hexa, Twinrix-Junior</intervention_name>
    <description>Vaccines administrated according to product monographs' recommendations</description>
    <arm_group_label>Infanrix-hexa+Infanrix-hexa</arm_group_label>
    <arm_group_label>Infanrix-hexa+Infanrix-hexa+Infanrix-hexa</arm_group_label>
    <arm_group_label>Infanrix-hexa+Twinrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Comparator group :

          -  have received 3 doses of Infanrix-hexa as part of the regular vaccination program at
             the age of 2, 4 and 18 months.

             • Study groups:

          -  have received 1 dose of Infanrix-hexa as part of the regular vaccination program at
             the age of 2 months.

        Exclusion Criteria:

          -  Have received other doses of hepatitis B vaccine;

               -  Be considered immunosuppressed;

               -  Have an autoimmune disease;

               -  Have contraindications to HBV vaccination, as defined in the Quebec Immunization
                  Protocol;

               -  Have a bleeding disorder;

               -  Be significantly delayed in development;

               -  Have or plan to participate in other clinical studies with vaccines or products
                  not approved in Canada;

               -  Have presented a serious clinical condition to the vaccines administered as part
                  of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>19 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laval University Research Hospital Center</name>
      <address>
        <city>Quebec</city>
        <zip>G1E7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Gilca, MD, PhD</last_name>
      <phone>4186667000</phone>
      <phone_ext>510</phone_ext>
      <email>vladimir.gilca@inspq.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Chantal Sauvageau, MD, MSc</last_name>
      <phone>4186667000</phone>
      <phone_ext>368</phone_ext>
      <email>chantal.sauvageau@inspq.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Vladimir Gilca, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Équipe de recherche en vaccination</name>
      <address>
        <city>Quebec</city>
        <zip>G1E7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Gilca, MD, PhD</last_name>
      <phone>418 666 7000</phone>
      <phone_ext>510</phone_ext>
      <email>vladimir.gilca@inspq.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>France Bouchard, RN</last_name>
      <phone>418 666 7000</phone>
      <phone_ext>323</phone_ext>
      <email>france.bouchard@ssss.gouv.qc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Two doses</keyword>
  <keyword>Infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual data will be shared with any other researchers outside of this study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

